The RNA Editing Market Size is valued at USD 15.2 billion in 2023 and is predicted to reach USD 23.1 billion by the year 2031 at a 5.60% CAGR during the forecast period for 2024-2031.
RNA editing performs a crucial role in the nervous system, immune response, and cellular adaptation. It is a key focus in biomedical research for its potential in treating genetic disorders, cancer, and other diseases where RNA modification could offer therapeutic benefits. RNA Editing is a molecular procedure in which some cells can make changes to specific nucleotides sequenced within an RNA molecule. It also includes insertion, Deletion, and base substitution of nucleotides within the RNA molecule. Hence, the adoption of RNA Editing is expected to increase in the near future as concerns grow over the healthcare sector.
The rising number of chronic diseases and disorders are the factors expected to drive the growth of the global RNA Editing market. Advancements in CRISPR-Based RNA editing, the rapid expansion of RNA editing, and increasing investment are some of the other factors estimated to augment the target market growth. Additionally, The increasing expansion of genome editing applications globally is expected to boost market expansion in the coming years.
Nevertheless, the target market's growth may be restricted by the COVID-19 outbreak, recalls of RNA therapeutic products, and off-target effects of RNA editing during the forecast period. Additionally, the global RNA Editing market is anticipated to generate lucrative revenue growth opportunities for players over the forecast period as a result of the expansion of R&D activities, government initiatives to incorporate sustainable components into production, and investments by prominent players.
Competitive Landscape
Some Major Key Players In The RNA Editing Market:
- QIAGEN N.V.
- ProQR Therapeutics NV
- Sirna Therapeutics, Inc.
- UniqueQuire NV
- LAVA Therapeutics N.V.
- Argenx SE
- Shape Therapeutics, Inc.
- Korro Bio, In.
- Beam Therapeutics, Inc.
- Arrowhead Pharmaceuticals, Inc.
- Other Market Players
Market Segmentation:
The RNA Editing market is categorized based on the type of RNA, application, and technique. The Type segment consists of messenger RNA Modification, Transfer RNA modification, Ribosomal RNA Modification. The application segment includes cancer, genetic disorders, and temporary maladies. By technique, the market is segmented into insertion/Deletion and Deamination.
Based On The Type Of RNA, The Messenger RNA Modification Segment Accounts For A Major Contributor To The RNA Editing Market.
The messenger, RNA Modification category, is expected to hold a major share of the global RNA Editing market. This is attributed to playing an important role in gene expression. In gene expression, the genetic information is transferred from the DNA to the ribosomes. Additionally, RNA modifications also control mRNA stability, localization, splicing, and translation efficiency.
The Deamination Segment Witnessed Growth At A Rapid Rate
The deamination segment is projected to grow at a rapid rate in the global RNA Editing market owing to growing concerns about the conversion of specific nucleotide bases within RNA molecules. Hence, with the growing demand for deamination, there is an increase in demand for RNA Editing in the healthcare sector.
In The Region, The North American RNA Editing Market Holds A Significant Revenue Share.
The North American RNA Editing market is expected to record the prominent market share in terms of revenue in the upcoming future. This can be attributed to the strong focus on healthcare in the region, with the increasing adoption of RNA Editing due to the rising cases of genome editing. In addition, the healthcare industry in the region is focusing on the production of RNA Editing technology. Growing research & development activities and rapid innovations in the region are the significant factors proliferating the growth of the desired market in the region. In addition, Asia Pacific region is likely to grow very fast in the global RNA Editing market due to growing collaborations among local academic institutions, biotech businesses, government initiatives, and increasing funding from foreign partners.
Recent Developments:
- In September 2023, Wave Life Sciences submitted a proposal for a clinical trial for WVE-006, their RNA editing candidate. Dosing for the experiment has started in the U.K. after approval. This remarkable advancement in the industry represents the first time an RNA Editing candidate has advanced to clinical trials.
RNA Editing Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 15.2 Bn |
|
Revenue Forecast In 2031 |
USD 23.1 Bn |
|
Growth Rate CAGR |
CAGR of 5.60% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type Of RNA, Application, And Technique |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
ProQR Therapeutics NV, Sirna Therapeutics, Inc., Shape Therapeutics, Inc., Korro Bio, In., Beam Therapeutics, Inc., QIAGEN N.V., UniquQuire NV, LAVA Therapeutics N.V., argenx SE, Arrowhead Pharmaceuticals, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
